Lillelundmalone1844

Oleosomes are oil containing micro-carriers of natural origin that is comprised of special Oleosin proteins embedded with a monolayer of phospholipids and having triacylglycerol core. Due to their unique structure and non-toxic to the biological system these oil carriers are becoming very eye-catching in the field of formulation development in the field of pharmacy. Consequently, it offers emoliency, occlusivity, self-emulsification, an antioxidant and film-forming property which leads to controlled and sustained release of encapsulated bio-actives. It is also feasible to load oil-soluble ingredients such as fragrance, vitamins (retinol), and lipophilic drug moieties inside the core. Being a natural carrier, it shows some stability issues (leakage of oil from the core, oxidation of the loaded oil, aggregation of oil droplets) which are controllable. In this review, we have focused on the various stability issues, techniques (coating, surface modification, solvents) to overcome those problems, how to load any lipophilic drug into the oil core, and linked patent research works in the field of formulation development.

Medicinal plants present activities against neurodegenerative diseases with potential for the pharmaceutical industries. Therefore, the objective of this study was to investigate the current panorama of patents and articles of Brazilian medicinal plants with pharmacological activities in the Central Nervous System (CNS), regarding such aspects as the number of patents by countries, areas of knowledge and technological maturity.

we carry out a technological exploration on the Questel Orbit® platform with the descriptors Agave sisalana P., Amburana cearenses A., Dimorphandra mollis B., Jatropha curcas L, Poincianella pyramidalis T. and Prosopis juliflora (Sw.) DC. with pharmacological activity, and a scientific exploration in PubMed and Science Direct associated with the CNS in the title, abstract and methodology.

A total of 642 patents were identified between the years 1999-2019. Elacridar India, China and Brazil are highlighted, 6th place, out of a total of 48 countries. Of these, 30 patents were not in the National Institute of Industrial Property and 10% are Brazilian in biotechnology and pharmaceutical products. Eleven articles were used in PubMed and Science Direct with scientific domains (anticancer, neuroprotection and anti-inflammatory). The Federal University of Bahia is highlighted, showing Technology Readiness Levels (TRL4), basic skills of pre-clinical research.

Brazilian public universities have a significant role in the scientific, technological and innovative development of therapeutic assets for CNS.

Brazilian public universities have a significant role in the scientific, technological and innovative development of therapeutic assets for CNS.

In Covid-19 infection, leukopenia, inflammation, and elevated liver enzymes are found in most patients. Also, vitamin D deficiency attenuate the immune system and predispose a person more susceptible to infection. In this context, we aimed to evaluate vitamin D, Electrolytes, Complete blood count, Liver enzymes, Urea, Creatinine, Albumin, CRP and ESR levels in patients with Covid-19.

We conducted a cross-sectional study on 118 patients with Covid-19 who were hospitalized from 2020/2/19 to 2020/4/3 in ICU. Serum levels of electrolytes, liver enzymes, blood factors, urea, creatinine, CRP and ESR as well as anthropometric parameters and serum vitamin D concentration were measured.

A total of 118 patients (80 male and 38 female) was enrolled in the study (65.05±15.75 years). Only 5.08% of patients had no risk factors and 55.9% had ≥ 2 risk factors. Diabetes (44.1%) and obesity (23.7%) were more common among patients. Laboratory finding showed that 80.50% of patients had hyponatremia, but other electrolytes included K, Mg, Ca and P were normal in majority of participants as well as CBC, Cr, Urea, Alb, ALT and ALKP. The AST concentration increased in most patients (66.94%). All patients had high levels of inflammatory factors such as CRP and ESR. The mean of 25-hydroxy-vitamin D levels in participants (25.95 ± 14.56 ng/mL) was lower than its levels in general papulation. However, it was not statistically significant (P= 0.88). A significant negative correlation found between vitamin D and ALT (P= 0.02, -0.21) as well as vitamin D and CRP (P= 0.05, -0.17).

Regarding to the regulatory role of vitamin D in immune system and low levels of vitamin D in Covid-19 infected patients, the evaluation of vitamin D levels and prescribe supplements if necessary is suggested.

Regarding to the regulatory role of vitamin D in immune system and low levels of vitamin D in Covid-19 infected patients, the evaluation of vitamin D levels and prescribe supplements if necessary is suggested.

We aimed to examine the differences in life-space mobility and quality of life (QoL) of patients with cardiovascular disease (CVD) between the pre- and post-nationwide state of emergency initiated by the Coronavirus disease 2019 (COVID-19) pandemic in Japan and to show the factors associated with the decrease in life-space mobility and QoL in these patients.

We undertook a longitudinal study of 20 of 51 consecutive CVD patients with coronary artery disease (CAD) who met the study criteria. We used the Life-Space Assessment (LSA) tool to evaluate Life-space mobility and assessed QoL with the five-level EuroQoL five-dimensional questionnaire (EQ-5D-5L) in Japanese.

The LSA scores and EQ-5D-5L QoL score decreased significantly from the pre- to post-nationwide state of emergency in Japan (p < 0.01). ΔLSA was significantly positively associated with body mass index and significantly negatively associated with knee extensor muscle strength and pre-LSA score (p < 0.05). There were no significant relation motility and QoL in CAD patients will require further study.Characterized by small, highly heterogeneous patient populations, rare disease trials magnify the challenges often encountered in traditional clinical trials. In recent years, there have been increased efforts by stakeholders to improve drug development in rare diseases through novel approaches to clinical trial designs and statistical analyses. We highlight and discuss some of the current and emerging approaches aimed at overcoming challenges in rare disease clinical trials, with a focus on the ultimate stakeholder, the patient.